LakeShore commences BLA submission to DRAP for rabies vaccine
The PIKA rabies vaccine leverages LakeShore Biopharma's PIKA adjuvant technology.
Regulation
US Border Protection warns pharma of risks with incorrect biologic importation
FDA declines to approve Zealand Pharma’s hypoglycaemia therapy in infants
WuXi debates sale of pharma operations as BIOSECURE Act advances
J&J clinches EC approval for first single-pill PAH combo
Pfizer to withdraw sickle cell treatment OXBRYTA from market
Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship efforts
EMA CHMP recommends MSD’s KEYTRUDA for gynaecological cancers
